Ansa Biotechnologies selects new SVP of R&D

Jeremiah Hanes, Ph.D., joins Ansa after more than a dozen years at PacBio.

Jack O'Brien

August 24, 2022

9:00 am

Jeremiah Hanes

Ansa Biotechnologies named Jeremiah Hanes, Ph.D., as the company’s SVP of R&D Tuesday morning.

Hanes joins Ansa after more than a dozen years at PacBio, where he served as VP of Reagents R&D. Hanes is also the inventor of more than 30 U.S.-issued patents and authored 28 peer-reviewed scientific publications.

“Jeremiah is a proven leader in the biotechnology industry who was instrumental in the development of ‘long-read’ sequencing technologies that have had a profound impact on genomics, diagnostics, and our understanding of the natural world,” Ansa CEO Daniel Lin-Arlow said in a statement.

From Our Partners

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

Partner Content

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

The evolution of patient needs and rising consumer expectations are shaping a new era in healthcare — one that calls for a paradigm shift in the pharmaceutical industry's approach to patient support.

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.